KFDA to settle down safety issue on Celebrex.

The KFDA decided to change labelling of all non-steroid anti-inflammatory drugs (NSAIDs) including celebrex, aceclofenac, meloxicam, ibuprofen and naproxen. Thus, the safety problem of Pfizer's Celebrex has been sorted out.

Managing director Cho Seong-ja said on Feb. 2 "we respect the KFDA's determination and the safety problem of Celebrex is now ended. Celebrex is a unique COX-2 inhibited ...